MindWalk Holdings (HYFT) Other Operating Expenses (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Other Operating Expenses of $70762.1 for Q2 2026, up 125.82% year-over-year from $31335.7 in Q2 2025, and up 135.84% quarter-over-quarter from -$197436.1 in Q1 2026.
MindWalk Holdings (HYFT) Other Operating Expenses (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Other Operating Expenses for 7 consecutive years, with $70762.1 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses rose 125.82% year-over-year to $70762.1; the TTM figure through Apr 2026 stood at -$443278.0 (up 14.04% YoY), while the FY2026 annual figure was -$448646.2, up 13.56% from the prior year.
- Other Operating Expenses advanced to $70762.1 in Q2 2026 per HYFT's latest filing, from -$197436.1 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $9.8 million in Q3 2022 and bottomed at -$12.3 million in Q2 2022.
- Historically, Other Operating Expenses has averaged $137513.8 across 5 years, with a median of -$7021.1 in 2023.
- Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 7858.36% — and 2025, when it tumbled 907.83%.
- MindWalk Holdings' Other Operating Expenses stood at $261254.7 in 2022, then tumbled by 35.07% to $169623.6 in 2023, then sank by 196.7% to -$164032.7 in 2024, then sank by 84.14% to -$302048.3 in 2025, then soared by 123.43% to $70762.1 in 2026.
- Business Quant data shows HYFT's Other Operating Expenses at $70762.1 in Q2 2026, -$197436.1 in Q1 2026, and -$302048.3 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 70,762.08 |
| Jan 31, 2026 | -197,436.10 |
| Oct 31, 2025 | -302,048.30 |
| Jul 31, 2025 | -14,555.71 |
| Apr 30, 2025 | -274,064.19 |
| Jan 31, 2025 | -74,669.25 |
| Oct 31, 2024 | -164,032.67 |
| Jul 31, 2024 | -2,921.25 |
| Apr 30, 2024 | 33,925.93 |
| Jan 31, 2024 | -86,547.41 |
| Oct 31, 2023 | 169,623.59 |
| Jul 31, 2023 | 163,326.43 |
| Apr 30, 2023 | 22,910.52 |
| Jan 31, 2023 | -11,120.92 |
| Oct 31, 2022 | 261,254.71 |
| Jul 31, 2022 | 9.75 Mn |
| Apr 30, 2022 | -12.32 Mn |
| Jan 31, 2022 | 5.44 Mn |
| Oct 31, 2021 | 3,282.77 |
| Jul 31, 2021 | 3.70 Mn |